These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34097975)

  • 1. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.
    He L; Bhat K; Ioannidis A; Zhang L; Nguyen NT; Allen JE; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    Radiother Oncol; 2021 Aug; 161():140-147. PubMed ID: 34097975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
    Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
    Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
    Bhat K; Saki M; Vlashi E; Cheng F; Duhachek-Muggy S; Alli C; Yu G; Medina P; He L; Damoiseaux R; Pellegrini M; Zemke NR; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    Proc Natl Acad Sci U S A; 2020 May; 117(20):11085-11096. PubMed ID: 32358191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
    Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma.
    Bhat K; Saki M; Cheng F; He L; Zhang L; Ioannidis A; Nathanson D; Tsang J; Bensinger SJ; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
    J Natl Cancer Inst; 2021 Aug; 113(8):1094-1104. PubMed ID: 33556960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
    Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
    J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
    He Y; Li J; Koga T; Ma J; Dhawan S; Suzuki Y; Furnari F; Prabhu VV; Allen JE; Chen CC
    Neuro Oncol; 2021 Mar; 23(3):400-411. PubMed ID: 32830856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of Rac-1.
    He L; Ioannidis A; Hoffman CJ; Arambula E; Joshi P; Whitelegge J; Liau LM; Kornblum HI; Pajonk F
    Cancer Res Commun; 2024 Jun; 4(6):1566-1580. PubMed ID: 38837899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
    Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
    Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
    Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
    J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.
    Caragher SP; Shireman JM; Huang M; Miska J; Atashi F; Baisiwala S; Hong Park C; Saathoff MR; Warnke L; Xiao T; Lesniak MS; James CD; Meltzer H; Tryba AK; Ahmed AU
    J Neurosci; 2019 Mar; 39(11):1982-1993. PubMed ID: 30651332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.